Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Liabilities and Shareholders Equity (2022 - 2025)

CervoMed's Liabilities and Shareholders Equity history spans 9 years, with the latest figure at $30.6 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 37.38% year-over-year to $30.6 million; the TTM value through Sep 2025 reached $150.4 million, up 25.25%, while the annual FY2024 figure was $43.1 million, 332.0% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $30.6 million at CervoMed, down from $38.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $53.2 million in Q2 2024 and bottomed at $3.4 million in Q2 2023.
  • The 4-year median for Liabilities and Shareholders Equity is $29.2 million (2022), against an average of $25.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity crashed 88.47% in 2023 before it surged 1481.07% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $4.2 million in 2022, then soared by 139.86% to $10.0 million in 2023, then surged by 332.0% to $43.1 million in 2024, then fell by 28.95% to $30.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Liabilities and Shareholders Equity are $30.6 million (Q3 2025), $38.1 million (Q2 2025), and $38.6 million (Q1 2025).